Comparative Pharmacology
Head-to-head clinical analysis: CHIRHOSTIM versus ZORBTIVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHIRHOSTIM versus ZORBTIVE.
CHIRHOSTIM vs ZORBTIVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic tripeptide (l-prolyl-l-lysyl-l-phenylalanyl) that stimulates phagocytosis via activation of mononuclear phagocytes and polymorphonuclear leukocytes through binding to formyl peptide receptors (FPRs), enhancing chemotaxis, superoxide production, and bactericidal activity. Also enhances natural killer (NK) cell activity and modulates cytokine release (e.g., IL-1, IL-6, TNF-α).
Recombinant human growth hormone that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathway, leading to increased IGF-1 production and promotion of linear growth.
Subcutaneous injection: 0.5 mg/kg once daily. Maximum dose: 40 mg/day.
ZORBTIVE (somatropin) 0.006 mg/kg subcutaneously once daily for growth hormone deficiency in adults. Dose may be titrated based on clinical response and serum IGF-1 levels.
None Documented
None Documented
Terminal elimination half-life is 14-16 hours; clinically, steady-state is achieved in approximately 3-4 days.
Terminal elimination half-life of ZORBTIVE is approximately 2.5 hours after subcutaneous administration. For intravenous administration, the half-life is shorter at 0.6 hours. The longer subcutaneous half-life reflects sustained absorption from the injection site.
Primarily renal (70-85% as unchanged drug); biliary/fecal (10-20%) with enterohepatic recirculation.
ZORBTIVE (somatropin) is eliminated primarily via the kidneys through glomerular filtration and tubular reabsorption. Approximately 70% of the dose is excreted renally as intact peptide, with 30% undergoing hepatic metabolism and biliary excretion. Fecal elimination accounts for less than 5%.
Category C
Category C
Growth Hormone
Growth Hormone